Case Studies

The Situation

A research team had generated in vivo proof-of-principle data showing that AAV gene therapy could treat a rare kidney disorder. The science was promising, but there was no development plan. The program existed as a scientific discovery. No candidate optimization strategy, no delivery approach defined (vector or physical delivery), no regulatory path, and no timeline. Leadership wanted to fill a strategic gap in the portfolio, which meant the plan needed to de-risk the program and reach the clinic as quickly as possible.

The Challenge

The gap between "this could work" and "here's how we get to IND" was wide. The team needed:

• A strategy to optimize the gene therapy candidate and select a lead
• The right preclinical models at each stage, including in vitro, ex vivo, disease-specific mouse models, and a large animal model (pig) for translationally relevant questions
• Biomarker strategy to measure what mattered at each stage
• Coordination across preclinical, CMC, device (for physical delivery), regulatory, and clinical planning
• Go/no-go decision criteria at each stage so resources were not committed past a failing program
• A timeline optimized for speed because of the portfolio imperative

What Was Built

A structured preclinical development roadmap from candidate optimization through lead selection through IND-enabling studies, with the nonclinical package designed around an accelerated approval pathway from the start. Each stage had explicit go/no-go decision gates. The critical path approach cut 14 months off the development timeline through specific decisions:

• In vitro screening tool to rapidly select a lead candidate rather than running lengthy in vivo comparisons upfront
• CRO selected because they already had the disease model validated and established, eliminating months of model development
• Animal model chosen for compatibility with the treatment approach, enabling faster study execution
• Large animal delivery work run in parallel with small animal efficacy rather than sequentially
• CMC and preclinical timelines aligned so manufacturing was not on the critical path
• Translationally relevant models built in early to boost confidence in clinical predictions and reduce late-stage risk

Risks were identified, weighed, and paired with mitigations. The plan integrated CMC, device, regulatory, and clinical considerations so the preclinical program did not advance in isolation.

The Result

The plan was accepted by senior leadership as the development roadmap for the program. The critical path approach cut 14 months from the projected development timeline. The program entered candidate optimization on the defined timeline. Studies were initiated with the recommended CROs.

The Situation

A seed-stage oligonucleotide therapeutics company was approaching investor conversations but had never organized its materials for external review. A previous data room existed but was poorly structured and would not survive close examination. Some documents existed but the narrative connecting them to the development strategy was missing.

The Challenge

The company needed to go from disorganized internal files to a data room that could withstand real investor diligence. That meant:

• A logical data room structure designed for how investors actually navigate diligence
• A development narrative that connected the science to the strategy and was supported by the data
• Identification of gaps in the preclinical data package, specifically what was missing that investors would expect to see
• Claims discipline, finding where the narrative made assertions the data did not actually support
• Competitive positioning that was honest and defensible
• Q&A preparation anticipating the questions investors would ask during diligence

What BridgeLine Did

Over 3-4 weeks, BridgeLine:

• Organized the data room with a structure built for investor and partner navigation, not internal convenience
• Rewrote the development narrative to connect the data to the strategy with claims that the evidence could actually support
• Identified missing preclinical data that investors would have expected to see and recommended what needed to be generated
• Flagged claims that extended beyond the data and either revised them or built the supporting context
• Addressed weak competitive positioning so the company could articulate its differentiation clearly
• Built Q&A preparation materials anticipating the diligence questions investors would ask

The Result

The company received a structured, investor-ready data room with a defensible development narrative, identified data gaps with a plan to close them, and Q&A preparation materials. The company entered active investor conversations within 2 weeks of delivery.

The Situation

A biologics program needed senior scientific leadership to define the study sequence, oversee CRO execution, review interim data, and advise leadership on program direction. The program had multiple studies planned but no structured decision framework for when to advance, modify, or stop.

What the Role Involved

Over 6+ months:

• Defined the study sequence, determining which studies to run and in what order, with explicit go/no-go criteria at each stage
• Designed a pilot efficacy study as a decision gate before committing to the full study, which would have cost $1M+. The pilot was structured to generate early signal data so leadership could make an informed go/no-go decision without committing full study resources upfront
• Made go/no-go recommendations based on interim data, presenting findings to leadership with clear rationale
• Advised leadership on program direction, connecting study-level results to broader development strategy
• Reviewed and revised CRO protocols before studies started, ensuring designs would generate decision-grade data
• Monitored CRO execution in real time, reviewing interim data as it came in rather than waiting for final reports